
Macrolide-resistant Mycoplasma pneumoniae: laboratory diagnosis and epidemiology
Review Kuenyoul Park1, Heungsup Sung2 1Department of Laboratory Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea2Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Correspondence to Heungsup Sung E-mail: sung@amc.seoul.kr Ann Clin Microbiol 2026;29(3):10. https://doi.org/10.5145/ACM.2026.29.3.10Received on 28 April 2026, Revised on 21 May 2026, Accepted on 26 May 2026, Published on 22 June 2026.Copyright © Korean Society of Clinical Microbiology.This is an Open Access article which is freely available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Mycoplasma pneumoniae is a leading atypical cause of community-acquired pneumonia in children and adults, and the prevalence of resistance to macrolides, the recommended first-line agents, varies markedly by region. Since the fastidious growth of M. pneumoniae makes phenotypic antimicrobial susceptibility testing impractical for routine use, clinical microbiology laboratories have focused on 23S rRNA gene-targeted molecular detection. This mini-review examines








